From a valuation perspective, Soligenix (USA Stocks:SNGX) presents a mixed bag for potential investors. On one hand, the company's low Price to Book ratio of
1.61X suggests that the stock may be undervalued relative to its assets. However, the company's financial health raises some concerns, with a significant operating loss of
$8.5M and a negative net income from continuing operations of
$8.1M. Furthermore, the company's working capital of
$3.36M is less than half of its current liabilities of
$7.41M, indicating potential liquidity issues. Therefore, while Soligenix may seem attractive from a valuation standpoint, investors should also consider the company's financial health before making a decision.
Main Points
Soligenix currently has liabilities of 3.49 million, with a Debt to Equity (D/E) ratio of 2.44. This suggests the company heavily relies on borrowing to finance its operations. With a current ratio of 2.31, Soligenix appears to have sufficient liquidity to meet its financial obligations when due. It's important to consider Soligenix's use of debt in conjunction with its cash and equity. We offer advice to supplement the current expert consensus on Soligenix. Our advanced recommendation engine uses a multidimensional algorithm to analyze the company's growth potential, incorporating all available technical and fundamental data.
We determine the current worth of Soligenix using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Soligenix based exclusively on its
fundamental and basic
technical indicators. By analyzing Soligenix's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of
Soligenix's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Soligenix. We calculate exposure to Soligenix's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Soligenix's related companies.
Soligenix Investment Alerts
Soligenix investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Soligenix performance across your portfolios.Please check all
investment alerts for Soligenix
Soligenix Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Soligenix value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Soligenix competition to find
correlations between indicators driving the intrinsic value of Soligenix.
What is driving Soligenix Investor Appetite?
The current price rise of Soligenix created some momentum for investors as it was traded today as low as
7.43 and as high as
7.43 per share. The company management teams may have good odds in positioning the company resources to exploit market volatility in
August. The stock standard deviation of daily returns for 90 days investing horizon is currently 35.22. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Soligenix partners.
| 2021 | 2022 | 2023 | 2024 (projected) |
Total Current Liabilities | 6.3M | 16.5M | 6.2M | 3.9M | Total Assets | 26.9M | 14.3M | 9.8M | 10.0M |
Margins Breakdown
Soligenix profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Soligenix itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Soligenix profit margins.
| Pretax Profit Margin | (9.92) |
| Operating Profit Margin | (10.68) |
| Net Profit Margin | (7.68) |
| Gross Profit Margin | 0.1 |
Soligenix Market Cap is increasing over the last 8 years. Soligenix Enterprise Value is fairly stable at the moment. Furthermore, Soligenix PTB Ratio is increasing over the last 8 years. The previous year's value of Soligenix PTB Ratio was 39.14.
Soligenix Market Cap is fairly stable at the moment. Soligenix Enterprise Value is increasing over the last 8 years. The current value of Soligenix Enterprise Value is 84,622,009. Furthermore, Soligenix PTB Ratio is increasing over the last 8 years. The current value of Soligenix PTB Ratio is 39.14. "Buy low, sell high" is a well-known investment mantra, but when it comes to Soligenix (USA Stocks:SNGX), the question is whether the current low price represents a buying opportunity. With a market capitalization of just $7.55M and a book value per share of 1.17X, the stock is trading at a relatively low price-to-book ratio of 1.61X. However, the company's financial health raises some concerns. Soligenix has a high probability of bankruptcy at 95.13%, and its operating margin is in the negative territory at -18.09, indicating significant losses. Furthermore, the company's net income stands at a loss of $6.1M. While the biotechnology industry is known for its high-risk, high-reward nature, investors should carefully consider these factors before adding Soligenix to their portfolio..
Another setback for Soligenix investors
Despite Soligenix's potential upside of over 11.42, recent performance has been disappointing, presenting a setback for investors. The company has struggled to capitalize on its potential, and while the increased upside suggests growth potential, it also highlights the risks of investing in the company. Investors should proceed with caution due to the stock's volatility, which could lead to significant losses. Soligenix's stock has shown above-average volatility over the selected period. Understanding market volatility trends can help investors time the market effectively. Using volatility indicators can help measure Soligenix's stock risk against market volatility during both bullish and bearish trends.
The heightened volatility of bear markets can directly affect Soligenix's stock price and stress investors as they watch their shares' value decrease, often prompting portfolio rebalancing with different financial instruments.Despite Soligenix's recent dip of over 2 percent, there is a strong case for considering an investment in the company. With a naive expected forecast value of
$10.02, the current analyst overall consensus labels Soligenix as a 'Strong Buy'. The analyst target price estimated value stands at $3.25, which presents a possible upside price of
$45.24, offering a substantial return potential for investors. However, as with any investment, it's crucial to weigh the risks. The possible downside price is $0.0743, suggesting a potential decrease in the stock's value. Thus, while Soligenix offers a promising upside, it is not without risk..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Soligenix. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
